Cynata Therapeutics (CYYNF)
(Delayed Data from OTC)
$0.19 USD
0.00 (0.00%)
Updated Jun 13, 2024 02:41 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Cynata Therapeutics Ltd. [CYYNF]
Reports for Purchase
Showing records 21 - 35 ( 35 total )
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Partnership Agreement Consummated With Fujifilm; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Partnership Agreement Consummated With Fujifilm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
UK Regulatory Agency Authorizes Phase 1 Trial Protocol; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
UK Regulatory Agency Authorizes Phase 1 Trial Protocol; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Non-Binding Term Sheet Signed With Fujifilm; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Non-Binding Term Sheet Signed With Fujifilm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
New Option License Agreement Inked with apceth; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
New Option License Agreement Inked with apceth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Strategic Alliance Inked in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Strategic Alliance Inked in Japan; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
MHRA Favorable Advice Received; Proceeding to Clinical Testing
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
MHRA Favorable Advice Received; Proceeding to Clinical Testing
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at Buy with A$1.00 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Cynata Therapeutics Ltd.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at Buy with A$1.00 Price Target
Provider: Rodman & Renshaw, Co.
Company: Cynata Therapeutics Ltd.
Industry: Unclassified
We initiate coverage on Cynata Therapeutics, Inc. with a price target of $1.55 per share.
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A